MOLECULAR PATHWAYS AND BIOMARKERS (MPB)

计划2.分子途径和生物标志物(MPB) 癌细胞的异常功能可以通过了解癌细胞的变化来进行研究。 动态平衡细胞信号事件的激活和沉默。功能蛋白质组的鉴定 癌细胞的特性允许理解其潜在的生物学，并提供独特的 关键结点的治疗靶向以及疾病生物标记物的开发机会 预防、检测和随访。分子途径和生物标志物的主要主题 该计划主要有三个领域，反映了对癌症基础科学研究的主要重视 信号体及其在临床翻译中的开发。MPB计划的主题领域包括(1)肿瘤 低氧与血管生成；(2)肿瘤-间质相互作用；(3)新影像技术的发展 和应用程序。 MPB计划的目标是： (I)阐明作为血管生成和靶向基础的细胞信号事件的机制 接受治疗。 (Ii)发现肿瘤-间质相互作用的关键介质，并确定预测原发肿瘤的生物标记物 肿瘤在远处的生长和转移。 (Iii)开发新的成像应用程序，以更好地检测癌症生长，帮助诊断癌症类型和 为后续治疗提供更准确的工具。 MPB计划由来自医学院15个部门的40名核心成员组成。 目前有30名资助计划核心成员。强制性公积金计划每年经同行评审的拨款总额为 1523万美元(直接1060万美元)，其中NCI资金为480万美元(330万美元直接)。在P20计划中 授权期内的2002-2008年间，MPB会员发表文章445篇。方案内协作 占110个(24.7%)，其中计划间协作占144个(32.4%) 出版物。

Program 2. Molecular Pathways and Biomarkers (MPB) The abnormal function of cancer cells can be investigated through the understanding of the changes in the activation and silencing of homeostatic cell signaling events. Identification of the functional proteome characteristic of a cancer cell permits the understanding of its underlying biology and provides unique opportunities for therapeutic targeting of critical node points as well as exploitation of biomarkers for disease prevention, detection and follow-up. The primary themes of the Molecular Pathways and Biomarkers program are in three main areas and reflect a major emphasis on basic science investigations of the cancer signalosome and its exploitation for clinical translation. The MPB Program's thematic areas include (1) tumor hypoxia and angiogenesis; (2) tumor-stroma interactions and (3) development of novel imaging technology and applications. The aims of the MPB program are: (i) to elucidate the mechanisms of the cellular signaling events that underlie angiogenesis and their targeting for therapy. (ii) To discover the key mediators of tumor-stromal interactions and identify biomarkers that predict primary tumor growth and metastasis at distant sites. (iii) To develop novel imaging applications to better detect cancer growth, help diagnose cancer type and provide more accurate tools for treatment follow-up. The MPB program is comprised of 40 core members from 15 departments within the School of Medicine. Currently there are 30 funded program core members. The total peer-reviewed funding per year of MPB is $15.23 M ($10.6 million direct), of which NCI funding represents $4.8 M ($3.3 M direct). In the P20 planning grant period of 2002-2008, MPB members published 445 articles. Intraprogrammatic collaborations accounted for 110 (24.7%) and interprogrammatic collaborations accounted for 144 (32.4%) of these publications.